Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q2 FY25 results · Jul–Sep 2024

Camlin Fine Sciences reported revenue from operations of ₹422.97 crore (up 4.2% from Q2 FY24) and net loss of ₹116.11 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	422.97	405.88	+4.2%	395.85	+6.9%
Other income	12.10	1.76	+587.0%	1.87	+547.7%
Total income	435.07	407.64	+6.7%	397.72	+9.4%
Profit before share of associates & JVs and tax	(142.81)	(12.09)	Loss widened	(23.48)	Loss widened
Share of profit/(loss) of associates & JVs	0.51	0.00		0.00
Net profit for the period	(116.11)	(20.83)	Loss widened	(34.65)	Loss widened
Attributable to shareholders of the company	(100.23)	(19.38)	Loss widened	(33.95)	Loss widened
EPS, basic (₹)	(5.98)	(1.17)	Loss widened	(2.03)	Loss widened
Net margin (%)	-27.5	-5.1		-8.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	226.91	206.21	+10.0%	181.91	+24.7%
Other income	3.08	5.63	−45.3%	1.78	+73.1%
Total income	229.99	211.85	+8.6%	183.69	+25.2%
Profit before tax	(110.54)	(0.52)	Loss widened	(17.60)	Loss widened
Net profit for the period	(72.62)	(1.46)	Loss widened	(13.68)	Loss widened
EPS, basic (₹)	(4.34)	(0.09)	Loss widened	(0.82)	Loss widened
Net margin (%)	-32.0	-0.7		-7.5

Consolidated

Filed with BSE: 11 Nov 2024, 17:15 IST
Board meeting: 11 Nov 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 11 Nov 2024, 17:15 IST
Board meeting: 11 Nov 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE